Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

in Endocrine-Related Cancer
Authors:
Marta Araujo-Castro Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain

Search for other papers by Marta Araujo-Castro in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-0519-0072
,
Betina Biagetti Department of Endocrinology and Nutrition, Hospital Universitario Vall de Hebrón, CIBERER U747 (ISCIII), ENDO-ERN, Barcelona, Spain

Search for other papers by Betina Biagetti in
Current site
Google Scholar
PubMed
Close
,
Edelmiro Menéndez Torre Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias & Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Asturias, Spain

Search for other papers by Edelmiro Menéndez Torre in
Current site
Google Scholar
PubMed
Close
,
Iría Novoa-Testa Department of Endocrinology and Nutrition, Hospital Universitario de A Coruña, A Coruña, Spain

Search for other papers by Iría Novoa-Testa in
Current site
Google Scholar
PubMed
Close
,
Fernando Cordido Department of Endocrinology and Nutrition, Hospital Universitario de A Coruña, A Coruña, Spain

Search for other papers by Fernando Cordido in
Current site
Google Scholar
PubMed
Close
,
Eider Pascual-Corrales Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain

Search for other papers by Eider Pascual-Corrales in
Current site
Google Scholar
PubMed
Close
,
Víctor Rodríguez Berrocal Department of Neurosurgery, Hospital Universitario Ramón y Cajal, Madrid, Spain

Search for other papers by Víctor Rodríguez Berrocal in
Current site
Google Scholar
PubMed
Close
,
Fernando Guerrero-Pérez Department of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Cataluña L’Hospitalet de Llobregat, Spain

Search for other papers by Fernando Guerrero-Pérez in
Current site
Google Scholar
PubMed
Close
,
Almudena Vicente Department of Endocrinology and Nutrition, Hospital Universitario de Toledo, Toledo, Spain

Search for other papers by Almudena Vicente in
Current site
Google Scholar
PubMed
Close
,
Juan Carlos Percovich Hualpa Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain

Search for other papers by Juan Carlos Percovich Hualpa in
Current site
Google Scholar
PubMed
Close
,
Rogelio García-Centeno Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain

Search for other papers by Rogelio García-Centeno in
Current site
Google Scholar
PubMed
Close
,
Laura González-Fernández Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain

Search for other papers by Laura González-Fernández in
Current site
Google Scholar
PubMed
Close
,
María Dolores Ollero García Department of Endocrinology and Nutrition, Hospital Universitario Navarra, Pamplona, Spain

Search for other papers by María Dolores Ollero García in
Current site
Google Scholar
PubMed
Close
,
Ana Irigaray Echarri Department of Endocrinology and Nutrition, Hospital Universitario Navarra, Pamplona, Spain

Search for other papers by Ana Irigaray Echarri in
Current site
Google Scholar
PubMed
Close
,
María Dolores Moure Rodríguez Department Endocrinology and Nutrition, Hospital Universitario de Cruces, Bilbao, Spain

Search for other papers by María Dolores Moure Rodríguez in
Current site
Google Scholar
PubMed
Close
,
Cristina Novo-Rodríguez Department of Endocrinology and Nutrition, Hospital Universitario Virgen de las Nieves, Granada, Spain

Search for other papers by Cristina Novo-Rodríguez in
Current site
Google Scholar
PubMed
Close
,
María Calatayud Department of Endocrinology and Nutrition, Hospital Universitario Doce de Octubre, Madrid, Spain

Search for other papers by María Calatayud in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-6737-7289
,
Rocío Villar-Taibo Department of Endocrinology and Nutrition, Hospital Universitario de Santiago de Compostela, Madrid, Spain

Search for other papers by Rocío Villar-Taibo in
Current site
Google Scholar
PubMed
Close
,
Ignacio Bernabéu Department of Endocrinology and Nutrition, Hospital Universitario de Santiago de Compostela, Madrid, Spain

Search for other papers by Ignacio Bernabéu in
Current site
Google Scholar
PubMed
Close
,
Cristina Alvarez-Escola Department of Endocrinology and Nutrition, Hospital Universitario La Paz, Madrid, Spain

Search for other papers by Cristina Alvarez-Escola in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0003-4448-7941
,
Pamela Benítez Valderrama Department of Endocrinology and Nutrition, Hospital Universitario La Paz, Madrid, Spain

Search for other papers by Pamela Benítez Valderrama in
Current site
Google Scholar
PubMed
Close
,
Carmen Tenorio-Jiménez Department of Endocrinology and Nutrition, Hospital Universitario Virgen de las Nieves, Granada, Spain

Search for other papers by Carmen Tenorio-Jiménez in
Current site
Google Scholar
PubMed
Close
,
Pablo Abellán Galiana Department of Endocrinology and Nutrition, Hospital General Universitario de Castellón, Castellón, Spain
Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain

Search for other papers by Pablo Abellán Galiana in
Current site
Google Scholar
PubMed
Close
,
Eva Venegas Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocío, Sevilla, Spain

Search for other papers by Eva Venegas in
Current site
Google Scholar
PubMed
Close
,
Inmaculada González-Molero Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, IBIMA Plataforma Bionand, Málaga, Spain

Search for other papers by Inmaculada González-Molero in
Current site
Google Scholar
PubMed
Close
,
Pedro Iglesias Department of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro, Madrid, Spain

Search for other papers by Pedro Iglesias in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0003-0126-1985
,
Concepción Blanco-Carrera Department of Endocrinology and Nutrition, Hospital Universitario Príncipe de Asturias, Madrid, Spain

Search for other papers by Concepción Blanco-Carrera in
Current site
Google Scholar
PubMed
Close
,
Fernando Vidal-Ostos De Lara Department of Endocrinology and Nutrition, Hospital Universitario Príncipe de Asturias, Madrid, Spain

Search for other papers by Fernando Vidal-Ostos De Lara in
Current site
Google Scholar
PubMed
Close
,
Paz de Miguel Novoa Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Madrid, Spain

Search for other papers by Paz de Miguel Novoa in
Current site
Google Scholar
PubMed
Close
,
Elena López Mezquita Department of Endocrinology and Nutrition, Hospital Universitario Clínico San Cecilio, Granada, Spain

Search for other papers by Elena López Mezquita in
Current site
Google Scholar
PubMed
Close
,
Felicia Alexandra Hanzu Department of Endocrinology and Nutrition, Hospital Clinic de Barcelona, Barcelona, Spain

Search for other papers by Felicia Alexandra Hanzu in
Current site
Google Scholar
PubMed
Close
,
Iban Aldecoa Biomedical Diagnostic Center, Department of Pathology, Hospital Clinic - University of Barcelona, Barcelona, Spain
Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain

Search for other papers by Iban Aldecoa in
Current site
Google Scholar
PubMed
Close
,
Silvia Aznar Department of Endocrinology and Nutrition, Hospital Universitario De Albacete, Albacete, Spain

Search for other papers by Silvia Aznar in
Current site
Google Scholar
PubMed
Close
,
Cristina Lamas Department of Endocrinology and Nutrition, Hospital Universitario De Albacete, Albacete, Spain

Search for other papers by Cristina Lamas in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0003-4622-9508
,
Anna Aulinas Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), Barcelona, Spain
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain

Search for other papers by Anna Aulinas in
Current site
Google Scholar
PubMed
Close
,
Queralt Asla Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), Barcelona, Spain
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain

Search for other papers by Queralt Asla in
Current site
Google Scholar
PubMed
Close
,
Paola Gracia Gimeno Department of Endocrinology and Nutrition, Hospital Royo Villanova, Zaragoza, Spain

Search for other papers by Paola Gracia Gimeno in
Current site
Google Scholar
PubMed
Close
,
José María Recio-Córdova Department of Endocrinology and Nutrition, Hospital Royo Villanova, Zaragoza, Spain

Search for other papers by José María Recio-Córdova in
Current site
Google Scholar
PubMed
Close
,
María Dolores Avilés-Pérez Department of Endocrinology and Nutrition, Hospital Universitario Clínico San Cecilio, Granada, Spain

Search for other papers by María Dolores Avilés-Pérez in
Current site
Google Scholar
PubMed
Close
,
Diego Asensio-Wandosell Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, Cataluña, Spain

Search for other papers by Diego Asensio-Wandosell in
Current site
Google Scholar
PubMed
Close
,
Miguel Sampedro-Núñez Department of Endocrinology and Nutrition, Hospital Universitario La Princesa Madrid, Spain

Search for other papers by Miguel Sampedro-Núñez in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-0089-4046
,
Rosa Cámara Department of Endocrinology and Nutrition, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Search for other papers by Rosa Cámara in
Current site
Google Scholar
PubMed
Close
,
Miguel Paja Fano Department of Endocrinology and Nutrition, OSI Bilbao-Basurto, Hospital Universitario de Basurto & University of the Basque Country UPV/EHU, Bilbao, Spain

Search for other papers by Miguel Paja Fano in
Current site
Google Scholar
PubMed
Close
,
Ignacio Ruz-Caracuel Department of Pathology, Hospital Universitario Ramón y Cajal, IRYCIS & CIBER Cáncer (CIBERONC), Madrid, Spain

Search for other papers by Ignacio Ruz-Caracuel in
Current site
Google Scholar
PubMed
Close
,
Carmen Fajardo Department of Endocrinology and Nutrition, Hospital Universitario La Ribera, Valencia, Spain

Search for other papers by Carmen Fajardo in
Current site
Google Scholar
PubMed
Close
,
Mónica Marazuela Department of Endocrinology and Nutrition, Hospital Universitario La Princesa Madrid, Spain

Search for other papers by Mónica Marazuela in
Current site
Google Scholar
PubMed
Close
, and
Manel Puig-Domingo Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, Cataluña, Spain

Search for other papers by Manel Puig-Domingo in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-6744-7195

Correspondence should be addressed to M Araujo-Castro or B Biagetti: marta.araujo@salud.madrid.org or betinaloys.biagetti@vallhebron.cat
Restricted access
Rent on DeepDyve

Sign up for journal news

The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and/or pegvisomant. Patients were classified in two groups: GH&PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs. All GH&PRL-Pit-NET cases treated with pasireotide (n = 6) and 82.6% (n = 19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&PRL-Pit-NETs (84.9% vs 66.7%, P = 0.178). We conclude that despite the more aggressive behavior of GH&PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors.

 

  • Collapse
  • Expand
  • Akirov A, Asa SL, Amer L, Shimon I & & Ezzat S 2019 The clinicopathological spectrum of acromegaly. Journal of Clinical Medicine 8. (https://doi.org/10.3390/JCM8111962)

  • Araujo-Castro M , Marazuela M, Puig-Domingo M & & Biagetti B 2023 Prolactin and growth hormone signaling and interlink focused on the mammosomatotroph paradigm: a comprehensive review of the literature. International Journal of Molecular Sciences 24 14002. (https://doi.org/10.3390/IJMS241814002)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Araujo-Castro M, Biagetti B, Torre ME, Novoa-Testa I, Cordido F, Corrales PE, Berrocal VR, Guerrero-Pérez F, Vicente A, Percovich JC, et al.2024 Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas: a series of 604 cases. Journal of Clinical Endocrinology and Metabolism. (https://doi.org/10.1210/clinem/dgae126)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Biagetti B, Iglesias P, Villar-Taibo R, Moure MD, Paja M, Araujo-Castro M, Ares J, Álvarez-Escola C, Vicente A, Álvarez Guivernau È, et al.2022 Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Frontiers in Endocrinology 13 984877. (https://doi.org/10.3389/FENDO.2022.984877)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Bogusławska A & & Korbonits M 2021 Genetics of acromegaly and gigantism. Journal of Clinical Medicine 10. (https://doi.org/10.3390/JCM10071377).

  • Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K, Lavenberg J, et al.2018 Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. European Journal of Endocrinology 179 419427. (https://doi.org/10.1530/EJE-18-0616)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Carmichael JD, Bonert VS, Nuño M, Ly D & & Melmed S 2014 Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 99 18251833. (https://doi.org/10.1210/JC.2013-3757)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, et al.2021 Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. European Journal of Endocrinology 184 217229. (https://doi.org/10.1530/EJE-20-0767)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Colao A, Auriemma RS, Lombardi G & & Pivonello R 2011 Resistance to somatostatin analogs in acromegaly. Endocrine Reviews 32 247271. (https://doi.org/10.1210/er.2010-0002)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, et al.2014 Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism 99 791799. (https://doi.org/10.1210/JC.2013-2480)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely AJ, Petrossians P, Potorac J, Muhammad A & & Neggers SJCMM 2020 T2-signal intensity, sstr expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. European Journal of Endocrinology 182 595605. (https://doi.org/10.1530/EJE-19-0840)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A & & Isidori AM 2019 Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. Journal of Clinical Endocrinology and Metabolism 104 28922902. (https://doi.org/10.1210/JC.2018-02281)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, et al.2021 A Pituitary Society update to acromegaly management guidelines. Pituitary 24 113. (https://doi.org/10.1007/s11102-020-01091-7)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, et al.2021 More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology 185 525538. (https://doi.org/10.1530/EJE-21-0239)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Franck SE, Muhammad A, van der Lely AJ & & Neggers SJCMM 2016 Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine 52 206213. (https://doi.org/10.1007/S12020-015-0810-8)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Kodama Lievre KK, et al.2014 Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet. Diabetes and Endocrinology 2 875884. (https://doi.org/10.1016/S2213-8587(1470169-X)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Gadelha M, Verônica Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, Santos E, Magalhães J & & Wildemberg LE 2023 Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience. Journal of Clinical Endocrinology and Metabolism 108 e1571e1579. (https://doi.org/10.1210/CLINEM/DGAD378)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KKY, et al.2014 Expert consensus document: a consensus on the medical treatment of acromegaly. Nature Reviews. Endocrinology 10 243248. (https://doi.org/10.1038/nrendo.2014.21)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, van der Lely AJ, Wass J, Melmed S & Acromegaly Consensus Group 2024 Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27 722. (https://doi.org/10.1007/S11102-023-01360-1)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Guo X, Zhang R, Zhang D, Wang Z, Gao L, Yao Y, Deng K, Bao X, Feng M, Xu Z, et al.2021 Hyperprolactinemia and hypopituitarism in acromegaly and effect of pituitary surgery: long-term follow-up on 529 patients. Frontiers in Endocrinology 12 807054. (https://doi.org/10.3389/fendo.2021.807054)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Haberbosch L & & Strasburger CJ 2023 Efficacy and safety of pegvisomant in the treatment of acromegaly. Archives of Medical Research 54 102884. (https://doi.org/10.1016/J.ARCMED.2023.102884)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J & & Bollerslev J 2012 Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 77 7278. (https://doi.org/10.1111/J.1365-2265.2011.04286.X)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ho KKY, Fleseriu M, Wass J, Katznelson L, Raverot G, Little AS, Castaño JP, Reincke M, Lopes MB, Kaiser UB, et al.2024 A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet. Diabetes and Endocrinology 12 209214. (https://doi.org/10.1016/S2213-8587(2300382-0)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Hassan Murad MH, Utz A, Wass JAH & Endocrine Society 2014 Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 99 39333951. (https://doi.org/10.1210/jc.2014-2700)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W, Jiang S & & Zhou P 2019 Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up. Endocrine 66 310318. (https://doi.org/10.1007/s12020-019-02029-1)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Marques-Pamies M , Gil J, Jordà M & & Puig-Domingo M 2023 Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly. Archives of Medical Research 54 102924. (https://doi.org/10.1016/J.ARCMED.2023.102924)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Muhammad A, Coopmans EC, Gatto F, Franck SE, Janssen JAMJL, van der Lely AJ, Hofland LJ & & Neggers SJCMM 2019 Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. Journal of Clinical Endocrinology and Metabolism 104 915924. (https://doi.org/10.1210/JC.2018-01524)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Obari A, Sano T, Ohyama K, Kudo E, Rong Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M & & Yamada S 2008 Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology 19 8291. (https://doi.org/10.1007/S12022-008-9029-Z)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, et al.2023 Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature Reviews. Endocrinology 19 722740. (https://doi.org/10.1038/S41574-023-00886-5)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Puig-Domingo M, Bernabéu I, Picó A, Biagetti B, Gil J, Alvarez-Escolá C, Jordà M, Marques-Pamies M, Soldevila B, Gálvez MA, et al.2021 Pasireotide in the personalized treatment of acromegaly. Frontiers in Endocrinology 12 648411. (https://doi.org/10.3389/FENDO.2021.648411)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ragonese M, Grottoli S, Maffei P, Alibrandi A, Ambrosio MR, Arnaldi G, Bianchi A, Puglisi S, Zatelli MC, De Marinis L, et al.2018 How to improve effectiveness of pegvisomant treatment in acromegalic patients. Journal of Endocrinological Investigation 41 575581. (https://doi.org/10.1007/S40618-017-0773-0)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Rick J, Jahangiri A, Flanigan PM, Chandra A, Kunwar S, Blevins L & & Aghi MK 2018 Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. Journal of Neurosurgery 131 147153. (https://doi.org/10.3171/2018.4.JNS18230)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ruiz S, Gil J, Biagetti B, Venegas E, Cámara R, Garcia-Centeno R, Gálvez , Picó A, Maraver S, González I, et al.2023 Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clinical Endocrinology 99 378385. (https://doi.org/10.1111/CEN.14946)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Shen M , Zhang Q, Liu W, Wang M, Zhu J, Ma Z, He W, Li S, Shou X, Li Y, et al.2016 Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58 10571065. (https://doi.org/10.1007/S00234-016-1728-4)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Sievers C, Baur DM, Schwanke A, Buchfelder M, Droste M, Mann K & & Stalla GK 2015 Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German acrostudy cohort. Pituitary 18 916923. (https://doi.org/10.1007/S11102-015-0673-2)

    • PubMed
    • Search Google Scholar
    • Export Citation